INKT

MiNK Therapeutics Inc

10.88

Oct 29 • 3:59 PM ET +0.07 (0.69%)

10.69

Aftermarket • 7:30 PM ET -0.19 (-1.70%)

Healthcare Biotechnology USA Micro NASD

Peers: NKTX FATE ACET IPSC AGEN ALLO CELU CRBU ATRA IBRX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	55.50M
Enterprise Value	46.69M
Income	-11.36M
Sales	0.00M
Book/sh	-2.75
Cash/sh	1.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Oct 15, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.30
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.23
Current Ratio	1.23
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-2.40
EPS next Y	-2.19
EPS next Q	-0.50
EPS this Y	24.74%
EPS next Y	0.68%
EPS next 5Y	7.42%
EPS past 3/5Y	29.40% 9.83%
Sales past 3/5Y	- -
EPS Y/Y TTM	15.65%
Sales Y/Y TTM	-
EPS Q/Q	41.49%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-3.33% -

Insider Own	60.10%
Insider Trans	-0.27%
Inst Own	4.00%
Inst Trans	8.64%
ROA	-187.78%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.88%
SMA50	-4.39%
SMA200	-3.74%
Trades

Shs Outstand	5.10M
Shs Float	2.04M
Short Float	2.34%
Short Ratio	3.39
Short Interest	0.05M
52W High	16.93 -35.75%
52W Low	8.48 28.24%
Volatility	8.33% 6.27%
ATR (14)	0.71
RSI (14)	50.12
Beta	0.47
Rel Volume	0.69
Avg Volume	14.08K
Volume	9,774

Perf Week	8.10%
Perf Month	-13.35%
Perf Quarter	3.57%
Perf Half Y	-10.86%
Perf YTD	-2.47%
Perf Year	-22.38%
Perf 3Y	19.44%
Perf 5Y	-93.92%
Perf 10Y	-
Recom	1.00
Target Price	42.05
Prev Close	10.80
Price	10.88
Change %	0.69%

Consensus

Strong Buy

Avg. Price Target

$42.05

Implied Upside

+286.7%

Analysts2incl. previous ratings

Rating Distribution1 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 15, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$35	+221.8%
Jul 14, 2025	Downgrade	WWilliam Blair	Outperform → Mkt Perform

Oct-02-26 09:00AM	MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 (GlobeNewswire)
Sep-30-26 07:57AM	MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy (GlobeNewswire)
Aug-13-26 07:07PM	MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ... (GuruFocus.com)
07:30AM	MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury (GlobeNewswire)
Aug-06-26 12:00PM	MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium (GlobeNewswire) -5.98%
08:19AM	Loading…
08:19AM	MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates (GlobeNewswire)
07:30AM	Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer (Business Wire)
Jun-03-26 04:30PM	MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting (GlobeNewswire) +6.69%
May-28-26 09:04AM	MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness (GlobeNewswire) +19.84%
May-21-26 05:00PM	Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 (Business Wire)
05:00PM	Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC (Business Wire)
May-20-26 11:07AM	MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications (GlobeNewswire)
May-15-26 07:01PM	MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -6.34%
04:11PM	Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer (Business Wire)
07:30AM	MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation (GlobeNewswire)
07:30AM	Loading…
May-14-26 07:30AM	MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness (GlobeNewswire)
May-12-26 07:35AM	MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 (GlobeNewswire)
May-11-26 08:45AM	Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development (Business Wire)
May-08-26 04:30PM	MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs (GlobeNewswire)
Apr-17-26 03:00PM	MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer (GlobeNewswire)
Apr-03-26 07:30AM	MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 (GlobeNewswire)
Apr-02-26 07:30AM	MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy (GlobeNewswire)
Apr-01-26 07:30AM	MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference (GlobeNewswire)
Mar-31-26 03:01PM	MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
07:30AM	MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum (GlobeNewswire)
Mar-17-26 07:30AM	MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs (GlobeNewswire)
Mar-10-26 09:47AM	MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally (Benzinga) +29.28%
05:30AM	MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers (GlobeNewswire)
Feb-03-26 09:30PM	MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia (GlobeNewswire)
Jan-08-26 12:00PM	MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease (GlobeNewswire)
11:42AM	Loading…
Nov-20-25 11:42AM	MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors (GlobeNewswire)
Nov-14-25 04:01PM	MiNK Therapeutics Inc (INKT) Q3 2025 Earnings Call Highlights: Promising Clinical Results and ... (GuruFocus.com) -5.88%
07:30AM	MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation (GlobeNewswire)
Nov-07-25 09:00AM	MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 (GlobeNewswire)
Nov-05-25 09:07AM	MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development (GlobeNewswire)
Oct-30-25 09:00AM	MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire)
Sep-29-25 07:30AM	MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors (GlobeNewswire)
Sep-25-25 07:30AM	MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA (GlobeNewswire) -5.09%
Sep-18-25 07:30AM	MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development (GlobeNewswire) +7.79%
Aug-22-25 05:40AM	New Strong Sell Stocks for August 22nd (Zacks)
Aug-15-25 09:32AM	Target downgraded, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Aug-14-25 07:30AM	MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results (GlobeNewswire) -12.46%
Jul-31-25 08:30AM	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report (GlobeNewswire) -8.34%
07:30AM	Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report (Business Wire)
Jul-15-25 08:21AM	MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy (GlobeNewswire) -31.03%
Jul-14-25 08:04AM	MiNK Therapeutics stock falls after William Blair downgrade (Investing.com) -36.71%
Jul-11-25 07:30AM	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer (GlobeNewswire) +730.14%
Jun-10-25 01:33PM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire) +5.84%
Jun-02-25 09:29AM	MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients (GlobeNewswire)
May-16-25 03:09AM	MiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +5.01%
May-15-25 11:48PM	Q1 2025 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress (GlobeNewswire)
May-05-25 12:30PM	MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report (GlobeNewswire)
Mar-19-25 03:01AM	MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-18-25 11:42PM	Q4 2024 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress (GlobeNewswire)
Mar-04-25 07:30AM	MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (GlobeNewswire) -7.88%
Feb-24-25 08:30AM	MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting (GlobeNewswire) +5.45%
Feb-20-25 07:30AM	MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Feb-12-25 01:00PM	MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting (GlobeNewswire) -7.86%
Jan-23-25 02:13PM	MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI (GlobeNewswire)
Dec-18-24 09:45AM	MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting (GlobeNewswire) -14.02%
Nov-15-24 02:17AM	Q3 2024 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:00AM	MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update (GlobeNewswire) -5.59%
Nov-11-24 07:30AM	MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report (GlobeNewswire)
Nov-07-24 10:00AM	MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 (GlobeNewswire)
Oct-31-24 09:15AM	MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors (GlobeNewswire)
Oct-09-24 06:15PM	MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 07:30AM	MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors (GlobeNewswire)
Oct-04-24 09:10AM	MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 (GlobeNewswire)
Sep-03-24 07:30AM	MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-13-24 07:00AM	MiNK Reports Second Quarter 2024 Results and Business Update (GlobeNewswire)
Aug-01-24 07:30AM	MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report (GlobeNewswire)
Jul-31-24 07:30AM	MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
Jul-11-24 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +11.36%
Jun-05-24 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-24 07:30AM	MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting (GlobeNewswire)
May-15-24 03:04AM	MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ... (GuruFocus.com) -7.14%
May-14-24 11:52AM	INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +14.31%
07:30AM	MiNK Reports First Quarter 2024 Results (GlobeNewswire)
May-13-24 07:30AM	MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer (GlobeNewswire) +8.87%
Apr-30-24 07:30AM	MiNK to Provide Corporate Update and First Quarter 2024 Financial Report (GlobeNewswire)
Apr-08-24 12:00PM	MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR (GlobeNewswire) -15.38%
Mar-25-24 12:00PM	All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy (Zacks) +5.47%
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:06PM	Q4 2023 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	MiNK Reports Fourth Quarter and Year-End 2023 Results (GlobeNewswire)
Mar-07-24 07:30AM	MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (GlobeNewswire)
Mar-06-24 08:30AM	MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 (GlobeNewswire)
Feb-14-24 08:00AM	First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab (GlobeNewswire) +7.75%
Feb-06-24 08:00AM	MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications (GlobeNewswire) +10.25%
Jan-30-24 08:00AM	MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene (GlobeNewswire)
Dec-20-23 07:30AM	ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development (GlobeNewswire)
Nov-09-23 08:05AM	MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges (GuruFocus.com) -6.72%
07:00AM	MiNK Therapeutics Reports Third Quarter 2023 Results (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buell Jennifer	Chief Executive Officer	Oct 12 '26	Sale	10.56	6,938	73,265	74,195	Oct 14 02:36 PM
Buell Jennifer	Officer	Oct 12 '26	Proposed Sale	10.56	6,938	73,275		Oct 13 08:36 AM
Ryan Barbara	Director	Jun 04 '26	Sale	12.76	1,500	19,141	21,969	Jun 05 06:04 PM
Ryan Barbara	Director	Mar 10 '26	Sale	15.40	1,300	20,017	20,406	Mar 11 06:22 PM
Ryan Barbara	Director	Mar 09 '26	Sale	10.17	200	2,034	21,706	Mar 11 06:22 PM
Ryan Barbara	Director	Feb 27 '26	Sale	10.86	400	4,343	22,006	Mar 04 04:45 PM
Ryan Barbara	Director	Mar 02 '26	Sale	10.83	100	1,083	21,906	Mar 04 04:45 PM

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.

Executive ChairmanDr. Garo H. Armen Ph.D.

Co-FounderDr. Jennifer S. Buell Ph.D.

Principal Financial OfficerMs. Melissa Orilall

Principal Accounting OfficerMr. Austin Charette

Head of Inflammatory & Pulmonary DiseasesDr. Terese C. Hammond M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INKT

MiNK Therapeutics Inc

Upgrade your Finviz experience